



## REFERENCES

## 參考資料

---



## REFERENCES 參考資料

1. Hong Kong Cancer Stats 2012. Hong Kong Cancer Registry, Hospital Authority, 2014.
2. Jatoi I, Anderson WF. Qualitative age interactions in breast cancer studies: a mini-review. *Future Oncol.* 2010;6(11):1781-8.
3. Feuer EJ, Wun LM, Boring CC, Flanders WD, Timmel MJ, Tong T. The lifetime risk of developing breast cancer. *J Natl Cancer Inst.* 1993;85(11):892-7.
4. Kouri EM, He Y, Winer EP, Keating NL. Influence of birthplace on breast cancer diagnosis and treatment for Hispanic women. *Breast Cancer Res Treat.* 2010;121(3):743-51.
5. Leung GM, Thach TQ, Chan E, Foo W, Meng O, Fielding R, Lam WW, Hedley AJ, Wong CM, Lam TH. Short-term, medium-term, long-term, and lifetime risks of developing and dying of breast carcinoma in a Westernized Chinese population: Evidence from Hong Kong between 1976 and 2000. *Cancer.* 2005;103(3):501-8.
6. Anders CK, Johnson R, Litton J, Phillips M, Bleyer A. Breast cancer before age 40 years. *Semin Oncol.* 2009;36(3):237-49.
7. Zhou P, Recht A. Young age and outcome for women with early-stage invasive breast carcinoma. *Cancer.* 2004;101(6):1264-74.
8. Beadle BM, Woodward WA, Buchholz TA. The impact of age on outcome in early-stage breast cancer. *Semin Radiat Oncol.* 2011;21(1):26-34.
9. International Agency for Research on Cancer. List of Classifications by cancer sites with sufficient or limited evidence in humans, Volumes 1 to 113. Available from <http://monographs.iarc.fr/ENG/Classification/index.php>. Accessed on 12 August 2015.
10. The Health Consequences of Smoking — 50 Years of Progress: A Report of the Surgeon General. Chapter 6: Cancer. Department of Health & Human Services (US);2014. 230 p. Available from <http://www.surgeongeneral.gov/library/reports/50-years-of-progress/sgr50-chap-6.pdf>. Accessed on 12 August 2015.
11. World Cancer Research Fund / American Institute for Cancer Research. Continuous Update Project Report. Food, Nutrition, Physical Activity, and the Prevention of Breast Cancer. 2010
12. Cheraghi Z, Poorolajal J, Hashem T, Esmailnasab N, Doosti Irani A. Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: a meta-analysis. *PLoS One.* 2012;7(12):e51446.
13. Collaborative Group on Hormonal Factors in Breast Cancer Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. *Lancet.* 2001;358:1389–1399.
14. Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA. Family history and the risk of breast cancer: a systematic review and meta-analysis. *Int J Cancer.* 1997;71(5):800–809.

15. Ibrahim EM, Abouelkhair KM, Kazkaz GA, Elmasri OA, Al-Foheidi M. Risk of second breast cancer in female Hodgkin's lymphoma survivors: a meta-analysis. *BMC Cancer*. 2012;12:197. doi: 10.1186/1471-2407-12-197.
16. Caini S, Boniol M, Botteri E, Tosti G, Bazolli B, Russell-Edu W, Giusti F, Testori A, Gandini S. The risk of developing a second primary cancer in melanoma patients: A comprehensive review of the literature and meta-analysis. *J Dermatol Sci*. 2014;75(1):3-9.
17. Jégu J, Colonna M, Daubisse-Marliac L, Trétarre B, Ganry O, Guizard AV, Bara S, Troussard X, Bouvier V, Woronoff AS, Velten M. The effect of patient characteristics on second primary cancer risk in France. *BMC Cancer*. 2014;14:94.
18. Youlden DR, Baade PD. The relative risk of second primary cancers in Queensland, Australia: a retrospective cohort study. *BMC Cancer* 2011; 11:83.
19. Chuang SC, Scélo G, Lee YC, Friis S, Pukkala E, Brewster DH, Hemminki K, Tracey E, Weiderpass E, Tamaro S, Pompe-Kirn V, Kliewer EV, Chia KS, Tonita JM, Martos C, Jonasson JG, Boffetta P, Brennan P, Hashibe M. Risks of second primary cancer among patients with major histological types of lung cancers in both men and women. *Br J Cancer*. 2010;102(7):1190-5.
20. Chaturvedi AK, Kleinerman RA, Hildesheim A, Gilbert ES, Storm H, Lynch CF, Hall P, Langmark F, Pukkala E, Kaijser M, Andersson M, Fossa SD, Joensuu H, Travis LB, Engels EA. Second cancers after squamous cell carcinoma and adenocarcinoma of the cervix. *J Clin Oncol*. 2009;27(6):967-73.
21. Zhou WB, Xue DQ, Liu XA, Ding Q, Wang S. The influence of family history and histological stratification on breast cancer risk in women with benign breast disease: a meta-analysis. *J Cancer Res Clin Oncol*. 2011;137(7):1053-60.
22. Urban M, Banks E, Egger S, Canfell K, O'Connell D, Beral V, Sitas F. Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: case-control study. *PLoS Med*. 2012;9(3):e1001182.
23. Li CI, Beaber EF, Tang MT, Porter PL, Daling JR, Malone KE. Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age. *Cancer Res*. 2012;72(8):2028-35.
24. Sweeney C, Giuliano AR, Baumgartner KB, Byers T, Herrick JS, Edwards SL, Slattery ML. Oral, injected and implanted contraceptives and breast cancer risk among U.S. Hispanic and non-Hispanic white women. *Int J Cancer*. 2007;121(11):2517-23.
25. Shapiro S, Rosenberg L, Hoffman M, Truter H, Cooper D, Rao S, Dent D, Gudgeon A, van Zyl J, Katzenellenbogen J, Baillie R. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. *Am J Epidemiol*. 2000;151(4):396-403.
26. Strom BL, Berlin JA, Weber AL, Norman SA, Bernstein L, Burkman RT, Daling JR, Deapen D, Folger SG, Malone KE, Marchbanks PA, Simon MS, Ursin G, Weiss LK, Spirtas R. Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer. *Contraception*. 2004;69(5):353-60.



27. Roth MY, Elmore JG, Yi-Frazier JP, Reisch LM, Oster NV, Miglioretti DL. Self-detection remains a key method of breast cancer detection for U.S. women. *J Womens Health (Larchmt)*. 2011;20(8):1135–9.
28. Ernst MF, Roukema JA, Coebergh JW, Repelaer van Driel OJ, van Beek MW, van der Sangen MJ, Voogd AC. Breast cancers found by screening: earlier detection, lower malignant potential or both? *Breast Cancer Res Treat*. 2002;76(1):19–25.
29. Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ. Influence of delay on survival in patients with breast cancer: a systematic review. *Lancet*. 1999;353(9159):1119–26.
30. Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Marcom PK, Mayer IA, McCormick B, Miller RS, Pegram M, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R; National Comprehensive Cancer Network Breast Cancer Panel. Breast cancer version 3.2014. *J Natl Compr Canc Netw*. 2014;12(4):542-90.
31. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. *AJCC cancer staging manual* (7th ed). New York. NY: Springer; 2010.
32. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel members. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. *Ann Oncol*. 2011;22(8):1736-47.